These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22729654)

  • 1. Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
    Catalá-López F
    Diabetologia; 2012 Sep; 55(9):2547-8; author reply 2549-50. PubMed ID: 22729654
    [No Abstract]   [Full Text] [Related]  

  • 2. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
    Bakris GL
    Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE.
    Lovshin JA; Cherney DZ
    Hypertens Res; 2014 Jan; 37(1):4-6. PubMed ID: 24026039
    [No Abstract]   [Full Text] [Related]  

  • 6. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 7. First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.
    Wang G; Chen Y; Li L; Tang W; Wright JM
    J Hum Hypertens; 2018 Jul; 32(7):494-506. PubMed ID: 29713053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.
    Bangalore S; Fakheri R; Toklu B; Messerli FH
    BMJ; 2016 Feb; 352():i438. PubMed ID: 26868137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of renin-angiotensin-system inhibitors.
    Parving HH; Rossing P
    Lancet; 2006 Mar; 367(9514):898-9; author reply 900-2. PubMed ID: 16546532
    [No Abstract]   [Full Text] [Related]  

  • 11. [Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
    Kanorskiĭ SG
    Kardiologiia; 2013; 53(10):89-95. PubMed ID: 24645559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?].
    Coca A; Ruilope LM
    Med Clin (Barc); 2000 Jul; 115(5):178-80. PubMed ID: 10996874
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?
    Marshall SM
    Diabet Med; 2004 Jan; 21(1):1-3. PubMed ID: 14706047
    [No Abstract]   [Full Text] [Related]  

  • 14. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting and controlling diabetic nephropathy: what do we know?
    Appel G
    Cleve Clin J Med; 2013 Apr; 80(4):209-17. PubMed ID: 23547091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
    Dézsi CA
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.